title: Bioprosthetic valve durability in the elderly: the second decade.
abstract: With an increasing number of elderly patients requiring cardiac valve surgery, the topic of bioprosthetic durability becomes critically important. Previous reports have shown expected survival of bioprosthetic valves to be in excess of 95% at 9 years. However, primary tissue failure appears to accelerate at the end of the first decade and there is limited data into the second decade. With this in mind, we proceeded to analyze all bioprosthetic valves implanted in patients 70 years of age and older. From September 1974 to December 1990, 781 patients underwent valve replacement using a bioprosthesis. Ages ranged from 70 to 88 years with a mean of 75.1. There were 423 males (54.2%) and 358 females (45.8%). Preoperatively, 99.0% of the patients were in either New York Heart Association functional Class III or IV. Fifty-nine patients (7.6%) were done as emergencies. Six hundred ninety-four patients left the hospital (30-day overall mortality 11.1%). In this cohort, there were 733 valves at risk. Follow-up extended from 1 to 186.0 months with a mean of 52.9, which resulted in 3,059.9 patient-years of cumulative follow-up. Bioprosthetic Survival: A total of 23 valves failed in the series; 15 primary tissue failures, seven from endocarditis, and one perivalvular leak. Actuarial survival at 7 years was 94.5% +/- 1.4% standard error of the mean (SEM; 168 valves at risk) and at 13 years, 83.7% +/- 4.8% SEM (11 valves at risk). This analysis provides further documentation of the long-term favorable durability of the bioprosthesis when utilized in patients 70 years of age and over.
authors.affiliation: St. Joseph's Heart Institute, Tampa, Florida.
authors.forename: D F
authors.initials: DF
authors.lastname: Pupello
authors.forename: L N
authors.initials: LN
authors.lastname: Bessone
authors.forename: S P
authors.initials: SP
authors.lastname: Hiro
authors.forename: E
authors.initials: E
authors.lastname: Lopez-Cuenca
authors.forename: M S
authors.initials: MS
authors.lastname: Glatterer
authors.forename: J C
authors.initials: JC
authors.lastname: Brock
authors.forename: W W
authors.initials: WW
authors.lastname: Angell
authors.forename: G
authors.initials: G
authors.lastname: Ebra
mesh_terms: D000206:Actuarial Analysis; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D001021:Aortic Valve; D001705:Bioprosthesis; D005260:Female; D006085:Graft Survival; D006350:Heart Valve Prosthesis / Q000009:adverse effects* / Q000401:mortality; D006801:Humans; D008297:Male; D008943:Mitral Valve; D015996:Survival Rate; D013997:Time Factors